ANI Pharmaceuticals (NASDAQ:ANIP) Shares Gap Down – Time to Sell?

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) gapped down before the market opened on Friday . The stock had previously closed at $90.23, but opened at $83.21. ANI Pharmaceuticals shares last traded at $93.6190, with a volume of 274,288 shares changing hands.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ANIP shares. Guggenheim raised their price objective on ANI Pharmaceuticals from $86.00 to $114.00 and gave the stock a “buy” rating in a research note on Monday, September 8th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th. HC Wainwright lifted their price target on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. JPMorgan Chase & Co. increased their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, October 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $99.14.

ANI Pharmaceuticals Trading Up 0.8%

The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of -118.88 and a beta of 0.54. The firm has a 50-day moving average of $93.64 and a 200 day moving average of $77.38.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The business had revenue of $227.81 million for the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The company’s revenue was up 53.6% on a year-over-year basis. During the same period in the previous year, the business earned $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, equities analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Insider Activity

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the stock in a transaction on Monday, October 13th. The stock was sold at an average price of $90.09, for a total transaction of $36,036.00. Following the completion of the transaction, the vice president directly owned 75,674 shares of the company’s stock, valued at approximately $6,817,470.66. This trade represents a 0.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Matthew J. Leonard sold 2,528 shares of the business’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $90.62, for a total value of $229,087.36. Following the completion of the sale, the director directly owned 6,864 shares in the company, valued at $622,015.68. This represents a 26.92% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 413,830 shares of company stock valued at $36,505,378 over the last 90 days. Corporate insiders own 12.70% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

Several large investors have recently made changes to their positions in ANIP. Principal Financial Group Inc. raised its holdings in shares of ANI Pharmaceuticals by 68.3% in the 1st quarter. Principal Financial Group Inc. now owns 157,798 shares of the specialty pharmaceutical company’s stock worth $10,565,000 after purchasing an additional 64,021 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in ANI Pharmaceuticals by 53.3% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,949 shares of the specialty pharmaceutical company’s stock worth $599,000 after buying an additional 3,112 shares during the last quarter. Invesco Ltd. grew its position in ANI Pharmaceuticals by 1.0% in the first quarter. Invesco Ltd. now owns 199,567 shares of the specialty pharmaceutical company’s stock worth $13,361,000 after buying an additional 2,022 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of ANI Pharmaceuticals by 0.9% in the first quarter. Charles Schwab Investment Management Inc. now owns 238,377 shares of the specialty pharmaceutical company’s stock valued at $15,959,000 after buying an additional 2,220 shares in the last quarter. Finally, Victory Capital Management Inc. lifted its position in shares of ANI Pharmaceuticals by 22.4% during the 1st quarter. Victory Capital Management Inc. now owns 16,863 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after acquiring an additional 3,086 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.